Aceragen | IDRA - Заемный капитал



Заемный капитал Изменить Дата
Abbott USD 29.64B 19.74B 2026-03
Agenus USD 169.66M 146.06M 2025-12
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
Amgen USD 51.89B 1.88B 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Cipla INR 3.82B 840.2M 2026-03
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Grifols EUR 9.95B 722.93M 2025-12
Merck USD 46.67B 77M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Pfizer USD 60.57B 1.08B 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
X T L Biopharmaceuticals USD 0 0 2024-12